Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers.

Trial Profile

Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2012

At a glance

  • Drugs TCN 032 (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2012 Results presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 15 May 2012 Positive top-line data from this trial have been reported in a Theraclone Sciences media release.
    • 21 Sep 2011 Status changed from not yet recruiting to recruiting, according to a Theraclone Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top